Immunology of tuberculosis, leprosy, malaria, and vaccines; Dean of Harvard School of Public Health
Awards
Bristol-Myers Squibb Award for Distinguished Research in Infectious Diseases (first awardee); Robert Koch Medal; Novartis Award for Clinical Immunology
Barry R. Bloom (born 1937) is an American immunologist known for his research on the immune response to infectious diseases, including tuberculosis, leprosy, malaria, and COVID-19. He is the Joan L. and Julius H. Jacobson Professor of Public Health, Emeritus in the Department of Immunology and Infectious Diseases and the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health, where he served as dean of the faculty from 1998 through 2008.[1]
Bloom has stated that the influence of the numerous physicians in his family led him to expect a medical career, before choosing immunology research instead.[2]
From 1978 to 1990, Bloom was chairman of the Department of Microbiology and Immunology at the Albert Einstein College of Medicine. In 1990, he became an investigator of the Howard Hughes Medical Institute, also serving on its national advisory board. In 1978 he acted as a consultant to the White House on international health policy.[3]
As dean of the Harvard School of Public Health (1998–2008), Bloom also served as secretary-treasurer of the Association of Schools of Public Health. He has held faculty appointments in the Departments of Immunology and Infectious Diseases and of Global Health and Population.
Research contributions
Bloom has been a leading scientist in immunology and global health. Much of his laboratory research has focused on host immune responses to Mycobacterium tuberculosis, defining vitamin D-dependent antimicrobial mechanisms in macrophages and developing aerosolized nanoparticle vaccine approaches.[4][5]
He chaired the WHO Technical and Research Advisory Committee to the Global Programme on Malaria, contributing to international strategies for malaria control and vaccine research.[6] He also chaired WHO committees on leprosy and tuberculosis research, and served on the Scientific and Technical Advisory Committee of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.
During the COVID-19 pandemic, Bloom provided expert analysis on vaccines and public health policy in national media and at Harvard press conferences.[7] In 2020 he was appointed to the Massachusetts state advisory committee on coronavirus vaccines.[8]
Bloom BR, Bennett B. "Mechanism of a reaction in vitro associated with delayed-type hypersensitivity." Science. 1966;153(3731):80–82.
Modlin RL, Bloom BR. "Immunologic mechanisms in leprosy." Annual Review of Immunology. 1984;2:41–60.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. "Toll-like receptor triggering of a vitamin D–mediated human antimicrobial response." Science. 2006;311(5768):1770–1773.
Bloom, Barry R.; Lambert, Paul-Henri (23 June 2016). The Vaccine Book (2nded.). San Diego: Academic Press (Elsevier). p.664. ISBN978-0-12-802174-3. Retrieved 22 September 2025.
A more complete list of publications is available at Harvard Catalyst.
Awards and honors
Bristol-Myers Squibb Award for Distinguished Research in Infectious Diseases (first awardee)
Novartis Award for Clinical Immunology (1998, shared)
Robert Koch Medal for lifetime research in infectious diseases (1999)
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
